Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors

Francesco Fiore, Michela Del Prete, Renato Franco, Vincenzo Marotta, Valeria Ramundo, Francesca Marciello, Antonella Di Sarno, Anna Chiara Carratù, Chiara De Luca Di Roseto, Annamaria Colao, Antongiulio Faggiano

Research output: Contribution to journalArticle

Abstract

Liver metastases from neuroendocrine tumor (NET) can be treated by transarterial embolization (TAE) or transarterial chemoembolization (TACE). The goal of TAE and TACE is to reduce blood flow to the tumor resulting in tumor ischemia and necrosis. In this retrospective study, the effectiveness and safety of TAE-TACE in the treatment of liver metastases in patients with NET was compared. Thirty patients with a histologically confirmed gastro-entero- pancreatic NET with liver metastases were retrospectively investigated. Seventeen patients underwent TAE, while 13 patients underwent TACE. Tumor response, degree of devascularization in treated lesions, and progression free survival (PFS) were evaluated in the whole population and then separately in TAE and TACE subgroups. In all patients treated with TAE and TACE, there was a significant size reduction of lesions as compared to baseline. Per lesion reduction was 2.2 ± 1.4 versus 3.3 ± 1.5 cm for TAE (p <0.001) and 2.2 ± 1.5 versus 3.4 ± 1.7 cm for TACE (p <0.001). In the whole population, the median PFS for all patients was 36 months (16.2-55.7 CI), without significant difference between TAE and TACE. In no patient did adverse events grade 3 and 4 as well as TAE/TACE-related death occurred, while the post-embolization syndrome occurred in 41 % of patients treated with TAE and 61 % of those treated with TACE. TAE and TACE are both effective in NET patients with liver metastases. TAE should be preferred to TACE in light of its similar anti-tumor effects and slightly better toxicity profile.

Original languageEnglish
Pages (from-to)177-182
Number of pages6
JournalEndocrine
Volume47
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Neuroendocrine Tumors
Neoplasm Metastasis
Liver
Disease-Free Survival
Neoplasms
Population
Necrosis
Ischemia
Retrospective Studies
Safety

Keywords

  • Chemoembolization
  • Embolization
  • Liver metastases
  • Neuroendocrine tumor

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. / Fiore, Francesco; Del Prete, Michela; Franco, Renato; Marotta, Vincenzo; Ramundo, Valeria; Marciello, Francesca; Di Sarno, Antonella; Carratù, Anna Chiara; De Luca Di Roseto, Chiara; Colao, Annamaria; Faggiano, Antongiulio.

In: Endocrine, Vol. 47, No. 1, 2014, p. 177-182.

Research output: Contribution to journalArticle

Fiore, F, Del Prete, M, Franco, R, Marotta, V, Ramundo, V, Marciello, F, Di Sarno, A, Carratù, AC, De Luca Di Roseto, C, Colao, A & Faggiano, A 2014, 'Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors', Endocrine, vol. 47, no. 1, pp. 177-182. https://doi.org/10.1007/s12020-013-0130-9
Fiore, Francesco ; Del Prete, Michela ; Franco, Renato ; Marotta, Vincenzo ; Ramundo, Valeria ; Marciello, Francesca ; Di Sarno, Antonella ; Carratù, Anna Chiara ; De Luca Di Roseto, Chiara ; Colao, Annamaria ; Faggiano, Antongiulio. / Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. In: Endocrine. 2014 ; Vol. 47, No. 1. pp. 177-182.
@article{d5c01c8d391c41d1a7e09cb72ed8aaf8,
title = "Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors",
abstract = "Liver metastases from neuroendocrine tumor (NET) can be treated by transarterial embolization (TAE) or transarterial chemoembolization (TACE). The goal of TAE and TACE is to reduce blood flow to the tumor resulting in tumor ischemia and necrosis. In this retrospective study, the effectiveness and safety of TAE-TACE in the treatment of liver metastases in patients with NET was compared. Thirty patients with a histologically confirmed gastro-entero- pancreatic NET with liver metastases were retrospectively investigated. Seventeen patients underwent TAE, while 13 patients underwent TACE. Tumor response, degree of devascularization in treated lesions, and progression free survival (PFS) were evaluated in the whole population and then separately in TAE and TACE subgroups. In all patients treated with TAE and TACE, there was a significant size reduction of lesions as compared to baseline. Per lesion reduction was 2.2 ± 1.4 versus 3.3 ± 1.5 cm for TAE (p <0.001) and 2.2 ± 1.5 versus 3.4 ± 1.7 cm for TACE (p <0.001). In the whole population, the median PFS for all patients was 36 months (16.2-55.7 CI), without significant difference between TAE and TACE. In no patient did adverse events grade 3 and 4 as well as TAE/TACE-related death occurred, while the post-embolization syndrome occurred in 41 {\%} of patients treated with TAE and 61 {\%} of those treated with TACE. TAE and TACE are both effective in NET patients with liver metastases. TAE should be preferred to TACE in light of its similar anti-tumor effects and slightly better toxicity profile.",
keywords = "Chemoembolization, Embolization, Liver metastases, Neuroendocrine tumor",
author = "Francesco Fiore and {Del Prete}, Michela and Renato Franco and Vincenzo Marotta and Valeria Ramundo and Francesca Marciello and {Di Sarno}, Antonella and Carrat{\`u}, {Anna Chiara} and {De Luca Di Roseto}, Chiara and Annamaria Colao and Antongiulio Faggiano",
year = "2014",
doi = "10.1007/s12020-013-0130-9",
language = "English",
volume = "47",
pages = "177--182",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors

AU - Fiore, Francesco

AU - Del Prete, Michela

AU - Franco, Renato

AU - Marotta, Vincenzo

AU - Ramundo, Valeria

AU - Marciello, Francesca

AU - Di Sarno, Antonella

AU - Carratù, Anna Chiara

AU - De Luca Di Roseto, Chiara

AU - Colao, Annamaria

AU - Faggiano, Antongiulio

PY - 2014

Y1 - 2014

N2 - Liver metastases from neuroendocrine tumor (NET) can be treated by transarterial embolization (TAE) or transarterial chemoembolization (TACE). The goal of TAE and TACE is to reduce blood flow to the tumor resulting in tumor ischemia and necrosis. In this retrospective study, the effectiveness and safety of TAE-TACE in the treatment of liver metastases in patients with NET was compared. Thirty patients with a histologically confirmed gastro-entero- pancreatic NET with liver metastases were retrospectively investigated. Seventeen patients underwent TAE, while 13 patients underwent TACE. Tumor response, degree of devascularization in treated lesions, and progression free survival (PFS) were evaluated in the whole population and then separately in TAE and TACE subgroups. In all patients treated with TAE and TACE, there was a significant size reduction of lesions as compared to baseline. Per lesion reduction was 2.2 ± 1.4 versus 3.3 ± 1.5 cm for TAE (p <0.001) and 2.2 ± 1.5 versus 3.4 ± 1.7 cm for TACE (p <0.001). In the whole population, the median PFS for all patients was 36 months (16.2-55.7 CI), without significant difference between TAE and TACE. In no patient did adverse events grade 3 and 4 as well as TAE/TACE-related death occurred, while the post-embolization syndrome occurred in 41 % of patients treated with TAE and 61 % of those treated with TACE. TAE and TACE are both effective in NET patients with liver metastases. TAE should be preferred to TACE in light of its similar anti-tumor effects and slightly better toxicity profile.

AB - Liver metastases from neuroendocrine tumor (NET) can be treated by transarterial embolization (TAE) or transarterial chemoembolization (TACE). The goal of TAE and TACE is to reduce blood flow to the tumor resulting in tumor ischemia and necrosis. In this retrospective study, the effectiveness and safety of TAE-TACE in the treatment of liver metastases in patients with NET was compared. Thirty patients with a histologically confirmed gastro-entero- pancreatic NET with liver metastases were retrospectively investigated. Seventeen patients underwent TAE, while 13 patients underwent TACE. Tumor response, degree of devascularization in treated lesions, and progression free survival (PFS) were evaluated in the whole population and then separately in TAE and TACE subgroups. In all patients treated with TAE and TACE, there was a significant size reduction of lesions as compared to baseline. Per lesion reduction was 2.2 ± 1.4 versus 3.3 ± 1.5 cm for TAE (p <0.001) and 2.2 ± 1.5 versus 3.4 ± 1.7 cm for TACE (p <0.001). In the whole population, the median PFS for all patients was 36 months (16.2-55.7 CI), without significant difference between TAE and TACE. In no patient did adverse events grade 3 and 4 as well as TAE/TACE-related death occurred, while the post-embolization syndrome occurred in 41 % of patients treated with TAE and 61 % of those treated with TACE. TAE and TACE are both effective in NET patients with liver metastases. TAE should be preferred to TACE in light of its similar anti-tumor effects and slightly better toxicity profile.

KW - Chemoembolization

KW - Embolization

KW - Liver metastases

KW - Neuroendocrine tumor

UR - http://www.scopus.com/inward/record.url?scp=84906933823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906933823&partnerID=8YFLogxK

U2 - 10.1007/s12020-013-0130-9

DO - 10.1007/s12020-013-0130-9

M3 - Article

C2 - 24385266

AN - SCOPUS:84906933823

VL - 47

SP - 177

EP - 182

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 1

ER -